{
    "clinical_study": {
        "@rank": "164862", 
        "acronym": "AVOCADO", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin 20mg, monotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Atorvastatin 20mg/day PO for 12weeks"
            }, 
            {
                "arm_group_label": "Atorvastatin 10mg, Fenofibric acid 135mg", 
                "arm_group_type": "Experimental", 
                "description": "Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare combination atorvastatin/fenofibric acid 10/135mg\n      with atorvastatin 20mg monotherapy in the mixed hyperlipidemia who were not at lipid goals\n      with atorvastatin 10mg monotherapy."
        }, 
        "brief_title": "Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Mixed Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hyperlipidemia, Familial Combined"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study conduct according to the standard operating procedure\n\n        -  The sponsor, the investigator, and all other persons involved in the study at the study\n           center or other facilities should conduct the study in accordance with the study\n           protocol, each standard operating procedure, and Korea Good Clinical Pratice.\n\n      Data quality control\n\n        -  In order to ensure the reliability of all study-related data and their appropriate\n           processing, the sponsor will apply quality control to each step of data handling\n\n      Monitoring\n\n        -  In order to confirm that the study is being conducted, recorded and reported according\n           to the study protocol and International Conference on Harmonization Good Clinical\n           Practice(ICH-GCP), the sponsor or CRO will perform monitoring of study procedure. In\n           monitoring, the monitors will cross check the description in the case report form, etc.\n           against study-related records such as source documents to confirm that the description\n           is accurate.\n\n      Measures taken to cope with adverse events and reporting procedure\n\n        -  The investigator should notify the event to the sponsor or Contract Research\n           Organization(CRO) immediately (within around 24 hours) after having noticed the\n           occurence of a serioius adverse event by telephone, fax or E-mail. The investigator\n           should complete and submit an serioius adverse event(SAE) report form containing all\n           information to the Institutional Review Board (IRB).\n\n      Data Management\n\n        -  In this study, data will be collected in electronic Case Report Form(CRF)\n\n        -  Data validation for missing data will be managed by computer programming and manual\n           check."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients of the age of 20years or older\n\n          -  patients who have been taking atorvastatin 10mg 1 tab per day for more than 8 weeks\n             before screening\n\n          -  patients who meet the following criteria\n\n               1. Low density lipoproteins-cholesterol level < 130mg/dL\n\n               2. 150mg/dL < Triglyceride level < 500mg/dL\n\n               3. HDL-cholesterol level < 45mg/dL\n\n          -  patients who consent for the consent before enrolling the study\n\n        Exclusion Criteria:\n\n          -  Allergic to HMG-CoA reductase inhibitor and fibrates\n\n          -  uncontrolled Hypertension\n\n          -  unstable angina, myocardial infarction, transient ischemic attack\n\n          -  uncontrolled diabetes\n\n          -  thyroid disease\n\n          -  myopathy, rhabdomyolysis history\n\n          -  alcoholic\n\n          -  chronic diarrhea, gastrointestinal disease\n\n          -  malignant tumor\n\n          -  patients who are pregnant\n\n          -  lactating woman"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "194", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974297", 
            "org_study_id": "AVOCADO"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atorvastatin 10mg, Fenofibric acid 135mg", 
                "description": "Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks", 
                "intervention_name": "Atorvastatin 10mg, fenofibric acid 135mg", 
                "intervention_type": "Drug", 
                "other_name": "Newvast 10mg, Fenocid 135mg"
            }, 
            {
                "arm_group_label": "Atorvastatin 20mg, monotherapy", 
                "description": "Atorvastatin 20mg/day PO for 12weeks", 
                "intervention_name": "atorvastatin 20mg", 
                "intervention_type": "Drug", 
                "other_name": "Newvast Tab. 20mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fenofibric acid", 
                "Atorvastatin", 
                "Fenofibrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hyperlipidemia", 
            "Atorvastatin", 
            "Fenofibric acid", 
            "combination", 
            "monotherapy"
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "contact": {
                "email": "SHL1106@hanmail.net", 
                "last_name": "Sang-Hak Lee, PhD", 
                "phone": "82-2-2228-8456"
            }, 
            "contact_backup": {
                "email": "jiyoung112@yuhs.ac", 
                "last_name": "Jiyeong Jeong, bachelor", 
                "phone": "82-2-2228-8277"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Severance Hospital, Yonsei University College of Medicine"
            }, 
            "investigator": {
                "last_name": "Sang-Hak Lee, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.", 
        "other_outcome": [
            {
                "measure": "changes of BUN/Cr level", 
                "safety_issue": "Yes", 
                "time_frame": "at screening and after 12 weeks"
            }, 
            {
                "measure": "Changes of Homocysteine level", 
                "safety_issue": "No", 
                "time_frame": "at screening and after 12 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Severance Hospital, Yonsei University College of Medicine", 
            "last_name": "Sang-Hak Lee, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "-change rate : [(12nd week non-High density lipoprotein - baseline non-High density lipoprotein) / baseline non-High density lipoprotein] * 100", 
                "measure": "Changes of non-HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "at screening and after 12 weeks"
            }, 
            {
                "description": "-Response rate : (subjects who are at less than 130mg/dL of non-High density lipoprotein level / all subjects) * 100", 
                "measure": "levelresponse rate of non-HDL cholesterol level < 130mg/dL", 
                "safety_issue": "No", 
                "time_frame": "at screening and after 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974297"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yonsei University", 
            "investigator_full_name": "Sang Hak Lee", 
            "investigator_title": "Associate Professor in Cardiology(preventive cardiology) in Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "19195513", 
                "citation": "Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22. doi: 10.1016/j.amjcard.2008.10.025. Epub 2008 Dec 26."
            }, 
            {
                "PMID": "20934572", 
                "citation": "Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J. 2010 Oct;160(4):759-66."
            }, 
            {
                "PMID": "19081418", 
                "citation": "Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203. doi: 10.1016/j.ahj.2008.08.027. Epub 2008 Nov 20."
            }, 
            {
                "PMID": "15247520", 
                "citation": "Kishikawa R, M-Horiuti T, Togawa A, Kondoh Y, Janzy PD, Goldblum RM, Kotoh E, Shimoda T, Shoji S, Nishima S, Brooks EG. [Juniper pollen monitoring by Burkard sampler in Galveston, Texas, USA and Japanese cedar pollen counting in Fukuoka, Japan -- introduction of Pan American Aerobiology Association protocol counting technique]. Arerugi. 2004 Jun;53(6):582-8. Japanese."
            }, 
            {
                "PMID": "18996523", 
                "citation": "Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May;204(1):208-15. Epub 2008 Oct 5."
            }, 
            {
                "PMID": "22592524", 
                "citation": "Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther. 2012 Jun;26(3):245-55. doi: 10.1007/s10557-012-6394-0. Review."
            }, 
            {
                "PMID": "17520105", 
                "citation": "Chatley P, Badyal DK, Calton R, Khosla PP. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):217-21."
            }, 
            {
                "PMID": "20110022", 
                "citation": "Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007."
            }, 
            {
                "PMID": "18650989", 
                "citation": "Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Iyer S, Shah KJ, Goyal RK. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007 Summer;12(2):91-6."
            }, 
            {
                "PMID": "20816118", 
                "citation": "Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol. 2010 Sep 15;106(6):787-92. doi: 10.1016/j.amjcard.2010.05.005. Epub 2010 Aug 2."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "changes of TC,HDL-C,LDL-C,TG,Apo B/A1", 
                "safety_issue": "No", 
                "time_frame": "at screening and after 12 weeks"
            }, 
            {
                "description": "HOMA-IR index = [fasting serum insulin(uU/mL) * fasting serum glucose(mmol/L)]/22.5", 
                "measure": "Changes of Glucose, HbA1c, HOMA-IR level", 
                "safety_issue": "No", 
                "time_frame": "at screening and after 12 weeks"
            }, 
            {
                "measure": "Changes of hs-CRP, adiponectin, resistin level", 
                "safety_issue": "No", 
                "time_frame": "at screening and after 12 weeks"
            }
        ], 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sang Hak Lee", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}